The Breast Cancer Research Foundation shared a post on LinkedIn:
“The FDA just approved Clairity Breast, the first-ever AI tool that predicts a woman’s breast cancer risk over the following 5 years—using only a mammogram.
This marks a major leap in early detection, equity, and personalized care and stands as powerful proof of the progress made possible with BCRF support.
Learn more about how it works and what this means for patients here.”
The Breast Cancer Research Foundation announced the FDA approval of Clairity Breast, a groundbreaking AI tool that forecasts a woman’s five-year breast cancer risk based solely on mammogram data. This innovation advances early detection and personalized screening strategies.
More posts featuring The Breast Cancer Research Foundation.
